SBS says Replimune investors may seek lead-plaintiff role in securities suit

By Atlas Watchline Staff · Legal · August 27, 2026

Schall, Brown & Schwartz LLP says Replimune shareholders may ask to be considered for lead-plaintiff status in a federal securities class action tied to the company’s BLA-related statements and FDA concerns.

Schall, Brown & Schwartz LLP said Wednesday that investors in Replimune Group, Inc. may seek lead-plaintiff appointment in a federal securities class action tied to the company’s Biologics License Application statements and concerns raised by the Food and Drug Administration.

The firm said shareholders who bought Replimune shares during the stated class period may contact it about possible lead-plaintiff appointments. It also said that status is not required to take part in any recovery.

What the press release says

The press release, issued by SBS and dated Aug. 27, 2026, identifies Replimune Group, Inc. as a Nasdaq-listed company under the ticker REPL. It says the lawsuit alleges violations of Section 10(b) and Section 20(a) of the Securities Exchange Act of 1934 and SEC Rule 10b-5.

According to the release’s summary of the complaint, Replimune made false and misleading statements to the market, failed to address FDA study-design concerns about its BLA, and submitted data from an unplanned analysis of the RP1-104 study. The release says that analysis included only 10% of the planned study enrollment.

The release also says the FDA was likely to reject the company’s BLA and that investors suffered damages when the market learned the truth.

Background and context

The class period listed in the release runs from Oct. 20, 2025, through Apr. 10, 2026. SBS said it is a national shareholder rights litigation firm and listed contact information for Brian Schall and David Schwartz in Los Angeles.

In securities cases, a lead plaintiff typically helps direct the lawsuit on behalf of other investors. SBS said investors who purchased REPL shares during the class period are encouraged to contact the firm about that role, and that appointment as lead plaintiff is not required to participate in any recovery.

What happens next

The press release does not give a court timetable. It says investors who think they were affected may contact SBS for more information about possible lead-plaintiff appointment.

Sources

• PR Newswire: Repl investors have opportunity to lead Replimune Group, Inc. securities fraud lawsuit with SBS Law

Editorial note: This article was prepared with AI assistance and includes source attribution for reader review.

This is the AMP version of the article. Read the full article on Atlas Watchline.